

## PHARMACY POLICY STATEMENT North Carolina Marketplace

<b>DRUG NAME</b>	<b>Ingrezza (valbenazine)</b>
BILLING CODE	Must use valid NDC
BENEFIT TYPE	Pharmacy
SITE OF SERVICE ALLOWED	Home
STATUS	Prior Authorization Required

Ingrezza is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia. Tardive dyskinesia (TD) is the most common type of tardive syndrome, which primarily involves abnormal, involuntary movements of the face. It is caused by antipsychotic medications or other drugs that block dopamine receptors. Severity of TD is assessed using the Abnormal Involuntary Movement Scale (AIMS), a 12-item scale with a total score range of 0 to 28, with a higher score translating to increased severity.

Ingrezza (valbenazine) will be considered for coverage when the following criteria are met:

### Tardive Dyskinesia (TD)

For **initial** authorization:

1. Member is 18 years of age or older; AND
2. Medication is prescribed by or in consultation with a neurologist or psychiatrist; AND
3. Member has a documented diagnosis of moderate to severe neuroleptic-induced TD; AND
4. Symptoms have been present at least 3 months and impede daily activities or quality of life; AND
5. Documentation of Abnormal Involuntary Movement Scale (AIMS) score must be in chart notes; AND
6. One or more of the following approaches has been attempted with inadequate symptom control:
  - a) The drug causing TD symptoms has been stopped and a different drug has been tried and/or
  - b) The member is clinically stable on the offending drug and the lowest effective dose is being used; AND
7. Chart notes confirm the member does not have increased risk for suicidal or violent behavior and has stable psychiatric symptoms; AND
8. If member has a history of substance use disorder, chart notes confirm the member is in remission.
9. **Dosage allowed/Quantity limit:** 40 mg once daily. After one week, increase the dose to the recommended dose of 80 mg once daily. (30 capsules per 30 days)

***If all the above requirements are met, the medication will be approved for 3 months.***

For **reauthorization**:

1. Documentation that the member's TD symptoms have improved due to Ingrezza use as evidenced by AIMS score showing reduction of score from baseline.

***If all the above requirements are met, the medication will be approved for an additional 12 months.***

CareSource considers Ingrezza (valbenazine) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.

DATE	ACTION/DESCRIPTION
08/29/2017	New policy for Ingrezza created.
12/14/2017	Criterion revised in collaboration with Indiana Medicaid DUR Board. Criterion requirement of clinical diagnoses of Schizophrenia or Schizoaffective Disorder, or Mood Disorder for at least 3 months was removed. Length of initial authorization increased to 3 months. Criterion on guidelines recommended treatment was revised.
12/28/2017	Criterion on negative drug test revised. Substance use disorder remission length requirement changed.
02/08/2018	New provider's specialty was added: nurse practitioner within a psychiatric or neurologic practice.
05/06/2019	The guideline recommended treatment criterion changed from two to one medication to try as a trial. Criterion on negative urine drug test or positive drug test result due to current prescriptions was removed.
12/21/2020	Updated quantity limit from 60 per 30 days to 30 per 30 days because a new strength (80 mg) is now available.
04/06/2022	Transferred to new template. Updated and added references. Removed NPs from specialist and added generalized "or in consultation with." Removed trial of clonazepam or ginkgo. Added that TD must be present for at least 3 months and with impeding symptoms. Removed list of exclusions. Removed duration from substance use disorder remission.

References:

1. Ingrezza [package insert]. San Diego, CA; Neurocrine Biosciences, Inc.: April, 2021.
2. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2017 Jun 9 - . Identifier NCT02274558, A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia (KINECT 3); 2017 Jun 9 [cited 2017 Jul 31]. Available from: <https://clinicaltrials.gov/ct2/show/NCT02736955?cond=ingrezza&rank=1>.
3. American Academy of Neurology. Summary of Evidence-based Guideline for PATIENTS and their FAMILIES. Treating and managing tardive syndromes. <https://www.aan.com/Guidelines/Home/GetGuidelineContent/614>.
4. Hauser RA, Factor SA, Marder SR, et al. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. *Am J Psychiatry*. 2017;174(5):476-484. doi:10.1176/appi.ajp.2017.16091037
5. Bhidayasiri R, Fahn S, Weiner WJ, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology [published correction appears in *Neurology*. 2013 Nov 26;81(22):1968]. *Neurology*. 2013;81(5):463-469. doi:10.1212/WNL.0b013e31829d86b6
6. Bhidayasiri R, Jitkriksadukul O, Friedman JH, Fahn S. Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm. *J Neurol Sci*. 2018;389:67-75. doi:10.1016/j.jns.2018.02.010
7. Solmi M, Pigato G, Kane JM, Correll CU. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. *Drug Des Devel Ther*. 2018;12:1215-1238. Published 2018 May 14. doi:10.2147/DDDT.S133205

Effective date: 01/01/2023

Revised date: 04/06/2022